Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 3, 2013)
-
-
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 19, 2013)
-
-
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Apr 4, 2013)
-
-
-
GlobeNewswire (Mar 18, 2013)
-
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 6, 2013)
-
-
-
-
-
-
-
-
-
-
Aastrom Biosciences Q3/11 Earnings ResultsHenry McCusker • Wed, Nov 9, 2011
-
-
Aastrom Biosciences' Trial Meets Safety and Efficacy EndpointsM. E. Garza • Thu, Jun 2, 2011
-
-
-
-
-
-
-
-
-
Talking With Aastrom Biosciences Execs: Previewing Clinical Trial InfoM. E. Garza • Mon, Nov 15, 2010
-
Aastrom Biosciences, Inc. Q2 2008 Earnings Call TranscriptFri, Feb 8, 2008
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 3, 2013)
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 19, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Apr 4, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 6, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
GlobeNewswire (Dec 12, 2012)
-
GlobeNewswire (Dec 10, 2012)
-
GlobeNewswire (Nov 26, 2012)
-
GlobeNewswire (Nov 20, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 5, 2012)
-
GlobeNewswire (Oct 29, 2012)
-
GlobeNewswire (Oct 4, 2012)
-
GlobeNewswire (Sep 19, 2012)
ASTM vs. ETF Alternatives
Company Description
We are a regenerative medicine company (a medical area that focuses on developing therapies that regenerate damaged or diseased tissues or organs) that incorporated in 1989 and focuses on the clinical development of autologous cell products (cells collected from a patient and returned to that... More
